摘要
目的探讨微生态制剂防治非酒精性脂肪性肝炎的作用机理。方法雄性SD大鼠50只随机分组为5组,每组10只,正常组普通饲料喂养;模型Ⅰ组、Ⅱ组喂高脂饲料;微生态制剂治疗组和饮食组分别在喂饲高脂饲料12周末予美常安灌胃和改为普通饲料喂养。12周末处死正常组、模型Ⅰ组大鼠;剩余2组大鼠继续喂养至16周末处死,测定血清转氨酶(ALT、AST),肿瘤坏死因子α(TNFα)水平,肝匀浆丙二醛(MDA)含量,超氧化物歧化酶(SOD)活性,总抗氧化能力(T-AOC),一氧化氮(NO)、诱导型一氧化氮合酶(iNOS)及谷胱甘肽(GSH)水平,观察肝组织学改变。结果模型组大鼠12周出现单纯性脂肪肝,16周发展为脂肪性肝炎。与正常组比,模型组大鼠肝组织脂质过氧化产物MDA含量明显增多(6.45±1.07,8.38±1.32μmol/gvs5.08±0.91μmol/g,P<0.01),而抗氧化物SOD(171±14,148±26kNU/gtvs198±25kKU/gt,P<0.05和P<0.01),GSH(40.8±5.1,35.0±9.0mg/gvs48.5±7.6mg/g,P<0.5和P<0.01)含量明显降低,且肝脏的脂肪变性严重程度随着高脂饮食喂养的时间延长而加剧,微生态制剂治疗组大鼠各项指标较模型组有明显改善(P<0.05或P<0.01),脂肪变性程度明显减轻,而饮食治疗组大鼠各项指标与模型组比无显著差异。结论微生态制剂美常安可能通过减轻体重,改善机体脂质代谢紊乱,抗脂质过氧化反应,抗炎等综合作用来防治非酒精性脂肪性肝炎。
Objective To explore the mechanisms of microbial pharmaceutics （MP） in the treatment of steatohepatitis in rats fed by high-fat diets. Methods 50 male Sprague Dawley rats were randomly assigned into 5 groups . The rats fed by normal food served as the controls. The rats in model groups（ Ⅰ,Ⅱ ） were fed with high-fat diets,and those in medication group were given MP 12 wk after high-fat diets feeding. The rats in diet therapeutic group were fed with normal food 12 wk after high-fat diet feeding. The animal in control and moder I group were killed at 12 wk, and the rest ones were killed at 16 wk. Blood sample were collected for the detection of serum aspartate transaminase（AST） ,alanine aminotransferase （ ALT）, and liver tissues were obtained for the detection of malondialdehyde （MDA） contents, superoxide dismutase （SOD） activity, total antioxidative capacity （T-AOC） , nitric oexide（NO） ,inducible nitric oxide synthase （iNOS） and glutathione （ GSH ） levels. The histological changes were observed under light microscope. Results Pure fatty liver formed in the model rats at 12 ,and fatty hepatitis was established at 16 wk. In comparison with those of normal rats,the contents of MDA increased（6. 45 ± 1. 07,8.38 ± 1. 32 μmol/g vs 5.08 ±0. 91 μmol/g, P 〈0. 01 ） but antioxide SOD（ 171 ± 14,148 ±26 kNU/gt vs 198 ±25 kNU/gt, P 〈0. 5 and P 〈0. 01） ,GSH（40. 8 ±5.1,35.0 ±9.0 mg/g vs 48.5 ±7.6 mg/g, P 〈0. 05 and P 〈0. 01 ） contents decreased significantly. The severity degree of hepatic fatty degeneration aggravated with the prolonging of the high-fat diet given time. In comparison with those of model rats,the markers such as MDA ,SOD,and GSH etc. were all significantly improved in the medication rats （ P 〈 0. 05 or P 〈 0. 01 ）, and the degree of fatty degeneration was also alleviated. Light or moderated fatty degeneration was observed in diet therapeutic rats, and the relative markers were not notably different from those of model group. Conclusion Microbial pharmaceutics mei chang an has therapeutic effect on nonalcoholic steatohepatitis by the action of lighting body weight, improving lipid metabolism disorder, antilipid peroxidation,and anti-inflammation.
出处
《临床消化病杂志》
2006年第6期350-352,共3页
Chinese Journal of Clinical Gastroenterology
关键词
微生态制剂
非酒精性脂肪性肝炎
Microbial pharmaceutics
Nonalcoholic steatohepatitis
